Find Academic Supervisors

Jude M. PhillipView profile

Assistant Professor

• Aging
• Mechanobiology
• Cancer Biology
• +5 more

Jude M. Phillip, PhD, is an Assistant Professor in the Departments of Biomedical Engineering and Chemical and Biomolecular Engineering at Johns Hopkins University. His research integrates engineering principles with aging and cancer biology to develop cell-based biomarkers and mechanistic insights into age-related diseases. He leads the Phillip tiME Lab, which focuses on aging dynamics, tumor microenvironment interactions, and translational technologies. Education : PhD, Chemical and Biomolecular Engineering, Johns Hopkins University, 2015 Postdoctoral Research, Melnick/Cerchietti Labs, Weill Cornell Medicine, 2016-2020 B.Eng, Chemical Engineering, City College of New York, 2010 Research Interests : Dr. Phillip’s work spans aging mechanisms, cancer biology, and mechanobiology. Key areas include: Cell-based biomarkers for aging and disease Scale-dependent aging pathways Lymphoma tumor-immune microenvironment (tiME) Single-cell profiling of senescence subtypes ECM mechanoregulation of stem cell fate His lab employs longitudinal cell profiling, data science, and clinical measures to bridge biological aging research with translational medicine. Recent Highlights : 2025: NIH R35 MIRA Award for lymphoma microenvironment research 2024: Johns Hopkins Catalyst Award for aging biomarker studies 2023: AFAR-Glenn Foundation Award for senescence subtype classification Lab & Collaborations : The Phillip Lab collaborates with the Institute for NanoBioTechnology and maintains a living patient-derived tumor biorepository for lymphoma studies. Current projects include ovarian aging organoid models and immune-mechanical interactions in cancer progression.

• Prostate Cancer
• Cancer Biology
• Translational Research
• +7 more

Professor Bill Watson is a Full Professor of Cancer Biology at the University College Dublin, School of Medicine , where he serves as Head of Pathology and Director of the Biomedical Health and Life Science BSc program. With a PhD in Biochemistry (University College Cork, 1995) and post-doctoral training at the University of Toronto, he has led translational research in prostate cancer since returning to UCD in 1997. His work focuses on biomarker discovery, therapy resistance mechanisms, and clinical decision tools through the Prostate Cancer Research Consortium and iPROSPECT collaborations. Education: BSc (University College Dublin), PhD (Royal College of Surgeons in Ireland), Post-Doctoral Research Fellow (Toronto General Hospital) His research integrates genomic, epigenetic, and proteomic biomarkers to improve prostate cancer stratification and treatment selection, as demonstrated in the Movember Global Action Plan and ToPCaP initiatives. Recent studies include validating a six-gene MCRS signature for biopsy-based prognostics (2025) and developing beta mixture models for DNA methylation analysis (2024). Scientific Awards include the Alton Prize (2000), Presidents Awards for Teaching (2000, 1998), and Young Investigator Award (1995). He has received grants such as the UCD Equip Scheme (2021) and Molecular Therapeutics for Cancer (2009-2015) . Professional Leadership: Irish Association for Cancer Research (President 2014-2017), Cancer Trials Ireland (Chair of Translational DSSG 2014-present), and Royal Academy of Medicine in Ireland (Fellow since 2006)

Grant MontgomeryView profile

Professor

• Genetics
• Genomics
• Reproductive Disorders
• +4 more

Professor Grant Montgomery is a leading academic at the University of Queensland (UQ), serving as Director of the UQ Genome Innovation Hub and Group Leader of the Genomics of Reproductive Disorders at the Institute for Molecular Bioscience (IMB). His primary focus is on understanding the genetic and epigenetic basis of reproductive disorders, particularly endometriosis, through large-scale genomic studies and functional analyses. His work integrates multi-omics data to identify disease mechanisms and develop translational solutions. Research Interests: Genetic and epigenetic regulation of endometrial function Systems genetics approaches to study complex diseases Functional validation of genomic risk variants Development of clinical tools like eQTL/mQTL browsers Multi-omics integration for disease biomarker discovery Recent Articles: Highlighting endometriosis genetics, comorbidity mechanisms, and novel diagnostic approaches. Key themes include genetic risk stratification, epigenetic dysregulation, and translational applications of genomic data. Collaborations: Active partnerships with institutions globally, including University of California, San Francisco, Oxford Endometriosis CaRe Centre, and Monash University. Major consortia include International Endometriosis Genetics Consortium and Reprogen Consortium. Advising & Training: Supervises PhD students focusing on endometrial cell biology, epigenetic regulation, and computational genomics. Provides training opportunities in functional genomics and systems biology. Labs/Teams: Leads a multidisciplinary team with expertise in molecular biology, bioinformatics, and clinical research. Maintains cell culture facilities and single-cell sequencing capabilities.

• Oncology
• Molecular Medicine
• Cancer Biology
• +5 more

Silvia Giordano is a Professor at the Department of Oncology, University of Turin. Her research focuses on oncology, molecular medicine, and cancer biology, with particular emphasis on gastric cancer, targeted therapies, and drug development. She contributes to courses like Basis of Human Morphology and Molecular bases of targeted therapies. Giordano leads studies on tumor cell signaling, resistance mechanisms, and translational models, including patient-derived xenograft (PDX) collections. She collaborates with institutions like the IRCCS Candiolo Cancer Institute and serves on academic bodies such as the Department Council. Her work bridges basic research and clinical applications, addressing challenges in cancer treatment and drug resistance. She has published extensively on topics like MET receptor biology, hepatocellular carcinoma models, and synergistic chemotherapy combinations.

• Acute Lymphoblastic Leukemia
• Pediatric Brain Tumors
• Genetic Heterogeneity
• +5 more

Stephen E. Sallan, MD , is a Professor of Pediatrics at Harvard Medical School and a Physician at Dana-Farber Cancer Institute and Children's Hospital . His career spans over five decades in pediatric hematology/oncology , with a focus on acute lymphoblastic leukemia (ALL) and pediatric brain tumors . Education : MD, Wayne State University School of Medicine (1967) Residencies : Boston Floating Hospital (1968), Children's Hospital of Philadelphia (1969), Hospital for Sick Children, London (1970) Fellowship : Pediatric Oncology, Children's Hospital/DFCI (1972) Leadership Roles : Chief of Staff (1995), Chairman of Medical Staff Executive Committee (1995), Chief of Staff Emeritus (2012) Dr. Sallan's research integrates genetic heterogeneity , disease recurrence , and drug resistance in ALL, with efforts to develop targeted therapies like tumor vaccines and antiangiogenesis agents. His work addresses long-term treatment toxicities (cardiac, skeletal, neurocognitive), particularly in survivors of childhood cancers. His 15 most recent publications (2024–2018) demonstrate ongoing engagement with pharmacogenomics, thrombosis risk models, dietary interventions, and molecular markers in brain tumors. Key subfields include TRK-C in medulloblastoma , asparaginase complications , and DFCI ALL Consortium Protocols . Scientific Awards : Distinguished Alumni Award, Wayne State University School of Medicine (1997) James Carreras Prize for International Pediatrician of the Year (1987) As a leader in pediatric leukemia research , Dr. Sallan has shaped treatment protocols that minimize late effects while improving survival. He collaborates with multidisciplinary teams in neuro-oncology and pharmacogenomics, maintaining active roles in clinical trials and laboratory investigations.

• Cancer Biology
• Biochemistry
• Cell Biology
• +3 more

Sonia Lain is a Professor at Karolinska Institutet's Department of Microbiology, Tumor and Cell Biology. She leads the 'Discovery and Elucidation of the mechanisms of Action of Tumour Selective Compunds' research group, part of the Division of Tumor Biology. Her work focuses on identifying molecules with therapeutic potential for cancer, particularly targeting DHODH (dihydroorotate dehydrogenase) inhibitors and p53 pathway activation. She holds a Docent degree from Karolinska Institutet (2012) and has been a professor since 2015. Her research integrates biochemistry, cell biology, and molecular oncology to develop novel cancer therapies. Research interests include tumor-selective compounds, pyrimidine metabolism, and the p53 signaling pathway. Her group investigates how DHODH inhibitors disrupt cancer cell proliferation while sparing normal cells. Key projects involve modulating nucleotide imbalance in tumors and understanding mechanisms of drug resistance. Publications highlight advancements in DHODH inhibitor mechanisms, metabolic effects of these compounds, and p53 activation strategies. The lab's work has been featured in journals like Nature Communications and Cell Chemical Biology . Collaborations with institutions like KTH and the University of Oxford underscore interdisciplinary approaches to drug discovery. No specific grants or awards are listed, but her group's research is supported by donations. She advises on lab activities but no formal student names are provided. The lab's future work includes optimizing DHODH inhibitors for clinical translation and exploring combination therapies.

Kelly VaughanView profile

Associate Professor

• Statistical Genetics
• Bioinformatics
• Genomics
• +3 more

Kelly Vaughan is the Chair and Associate Professor of Biology at King University. Her academic journey includes a BS in Biochemistry and Animal Science from Berry College, a PhD in Biochemistry from Texas A&M University, and postdoctoral work at the University of Alabama at Birmingham (UAB), where she later served as a Research Assistant Professor in Biostatistics. Her expertise spans statistical genetics, bioinformatics, and interdisciplinary genomics research. She transitioned to academia to focus on undergraduate research mentorship, emphasizing hands-on laboratory experience and Women in STEM advocacy. Her research integrates functional genomics and pathway analysis, addressing complex diseases such as obesity, rheumatoid arthritis, and cancer. A pivotal moment in her career was her 2015 cancer diagnosis, which underscored her commitment to holistic education and resilience. She actively involves students in regional and national conferences, fostering their integration into scientific communities. Her work highlights methodological rigor in genetic analysis and the ethical use of genomic data. Key contributions include studies on genetic loci associated with metabolic traits in Indigenous populations, gene expression in rheumatoid arthritis, and the impact of dietary interventions on aging biomarkers. Her teaching philosophy merges clinical relevance with cutting-edge research, aiming to inspire future scientists through both classroom and lab experiences.

Stephen J. ElledgeView profile

Professor

• DNA Damage Response
• Cell Cycle Regulation
• Cancer Biology
• +5 more

Stephen J. Elledge is the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School , with a primary appointment in the Department of Genetics and affiliations at Brigham and Women's Hospital (BWH) . His research focuses on cellular stress responses, particularly DNA damage signaling, and the development of genetic technologies for cancer gene discovery.

Markus PfirrmannView profile

Professor

• Clinical Epidemiology
• Biostatistics
• Leukemia Research
• +3 more

Markus Pfirrmann serves as Professor at the Institute of Medical Informatics, Biometry and Epidemiology (IBE) of Ludwig Maximilian University since 2024. He leads the "Registry Studies and Clinical Trials II" working group, focusing on advanced statistical methodology in clinical research. With a Master's in Applied Stochastic Systems from University College London and habilitation at LMU Munich (2016), his work bridges clinical questions and biostatistical innovation. Research Pillars Prognostic score development for leukemia Survival analysis with time-dependent covariates Competing risk modeling in clinical trials Therapy-free remission prediction Pharmacogenomic biomarker discovery His 30+ years of clinical trial leadership includes major studies like the CML V TIGER and EURO-SKI trials. Notable achievements include co-developing the EUTOS long-term survival score and receiving the Paul Martini Prize. Current methodological work emphasizes minimal residual disease monitoring and treatment de-escalation strategies. Scientific Awards Paul Martini Prize (2000) for medical informatics contributions As educator, he organizes the annual "Understanding Modern Statistics in Leukemia Trials" workshop at European LeukemiaNet symposiums and teaches clinical research methodology at Johannes Kepler University Linz. His 70+ peer-reviewed publications across Blood , Leukemia , and Lancet Oncology establish him as a key biostatistical authority in myeloid malignancies.

Sheri HolmenView profile

Professor

• Melanoma biology and therapy resistance
• Glioblastoma and pediatric glioma
• Brain metastasis mechanisms
• +5 more

Sheri Holmen, Ph.D. is a Professor of Surgery and Adjunct Professor of Oncological Sciences at the University of Utah, and co-leads the Cell Response and Regulation Program and Melanoma Center at the Huntsman Cancer Institute (HCI). Her laboratory employs sophisticated genetically-engineered mouse models to dissect the molecular circuitry governing melanoma and glioblastoma initiation, progression, and therapeutic resistance. Education: B.S. – Western Michigan University Ph.D. – Mayo Clinic College of Medicine Research Focus: Dr Holmen’s team concentrates on high-priority oncogenic pathways—PI3K/AKT/mTOR, MAPK, and focal adhesion kinase (FAK)—leveraging conditional RCAS/TVA retroviral systems to introduce precise genetic alterations in melanocytes and neural progenitors. The overarching goal is to uncover tractable therapeutic targets for metastatic melanoma and glioblastoma, particularly brain metastases that portend dismal prognosis. Scientific Impact & Trends: Across more than 100 peer-reviewed publications since 2012, Holmen’s group has demonstrated convergent mechanisms of resistance to BRAF/MEK inhibition, identified ARF6-mediated immune evasion, and validated combinatorial FAK + RAF/MEK blockade as a strategy to overcome micro-environmental resistance. Their 2024–2025 output emphasises metabolic liabilities (OXPHOS, CNDP1) and rational immunotherapy combinations. Current Funding & Collaborations: Principal investigator on multiple NCI-funded R01 and P30 awards via HCI. Founding steering committee member of the international InterMEL consortium (>2,000 early-stage melanomas) to discover prognostic biomarkers. Co-investigator on Utah Genome Project and Oncology Research Information Exchange Network initiatives. Laboratory & Resources: The Holmen laboratory occupies modern space within the HCI research tower and maintains dedicated SPF animal facilities for RCAS/TVA modelling, high-throughput drug screening suites, and single-cell genomics cores. Cross-disciplinary teams include bioinformaticians, translational pharmacologists, and clinician-scientists to accelerate bench-to-bedside translation.

• Cancer Biology
• Radiation Oncology
• Targeted Therapy Development
• +5 more

Dr. Kenneth Westover is an Associate Professor of Radiation Oncology and Chief of Lung Radiation Oncology Service at UT Southwestern Medical Center. He also serves as co-director of the Simmons Comprehensive Cancer Center’s thoracic disease-oriented team and Director of Clinical Innovation and Information Systems in the Department of Radiation Oncology. His research focuses on developing targeted therapies for RAS and kinase-driven cancers, with breakthroughs in KRAS G12C inhibitors influencing FDA-approved drugs like sotorasib and adagrasib. Clinically, he innovates software tools for radiation oncology operations and explores adaptive radiation techniques for lung cancer patients, including SAbR/SBRT fraction timing optimizations and MRI-guided systems. He leads the Westover Lab, integrating protein chemistry, structural biology, and informatics to advance oncology therapies. Education: Bachelor’s in Biochemistry, Brigham Young University Ph.D. and M.D., Stanford University Radiation Oncology Residency, Harvard Radiation Oncology Program Research Interests: Targeted therapy development for RAS and kinase mutations Mechanistic studies of RAS signaling and drug resistance Adaptive radiation therapy strategies for lung cancer Clinical innovation in radiation oncology operations Advising & Grants: Leads the Westover Lab, directing multidisciplinary teams in drug discovery and clinical innovation. Oversees clinical software implementations (e.g., RO-PAD, EPIC integration) and manages grants focused on translational oncology and radiation therapy optimization. Labs/Teams: The Westover Lab at UT Southwestern, collaborating with Simmons Comprehensive Cancer Center and Harvard-affiliated institutions.

Katja LamiaView profile

Professor

• Circadian Biology
• Metabolic Physiology
• DNA Damage Response
• +7 more

Katja Lamia is a Professor and Associate Dean of Graduate Studies in the Department of Molecular and Cellular Biology at Scripps Research. Her lab focuses on circadian clock regulation of metabolism, DNA damage responses, and cancer progression. She holds a PhD in Biophysics from Harvard (2003) and a B.A. in Physics from UC Berkeley (1996). Educations: PhD (Biophysics, Harvard 2003), BA (Physics, UC Berkeley 1996) Research Interests: Circadian clocks' roles in tumor suppression, metabolic homeostasis, and exercise physiology. Specific projects include HIF2α regulation in renal cancer, CRY protein tumor suppression mechanisms, and circadian-chronopharmacology. Notable achievements include discovering circadian disruption's role in HSF1-driven lung cancer progression and identifying CRY proteins' roles in suppressing mutations. Her work bridges molecular mechanisms with translational cancer therapies. Awards: Searle Scholars Award (2012), Sidney Kimmel Cancer Research Scholar (2013), Aschoff’s Rule Award (2016) Lab Location: 10550 North Torrey Pines Road, La Jolla CA 92037 Current investigations explore BMAL1-HIF2α interactions in kidney cancer, circadian regulation of exercise benefits, and cryptochrome's roles in tumor suppression. Her research emphasizes time-dependent therapeutic strategies for metabolic diseases and oncology.

Ali BashashatiView profile

Associate Professor

• Machine Learning
• Cancer Genomics
• Computational Biology
• +3 more

Dr. Ali Bashashati is an Associate Professor at the University of British Columbia (UBC), affiliated with the School of Biomedical Engineering and the Department of Pathology and Laboratory Medicine. He leads the Artificial Intelligence in Medicine (AIM) Lab, focusing on advancing healthcare through AI-driven solutions in computational pathology and omics data integration. His research combines machine learning, signal processing, and software engineering to address challenges in cancer diagnosis and treatment, particularly in breast, ovarian, and lymphoid cancers. Dr. Bashashati’s work emphasizes multi-modal data analysis, including histopathology imaging and genomics, to improve cancer subtyping and treatment stratification. He has pioneered frameworks like VOLTA for context-aware cell representation learning, enhancing AI models’ performance in histopathology analysis. His contributions to cancer genomics include studies on clonal evolution, tumor heterogeneity, and genomic instability mechanisms. He is the principal investigator of the NSERC CREATE MUSIC training program, a $1.65M initiative fostering next-generation biomedical engineers skilled in AI, biotechnology, and disease biology. This program integrates courses on medical imaging data analysis, applied machine learning, and multi-scale computing for healthcare innovation. Awarded the NSERC CREATE Grant, Dr. Bashashati’s lab collaborates with industry and academia to translate AI innovations into clinical practice, with over 200 peer-reviewed publications in top-tier journals like Nature and Nature Genetics. His team’s work spans from fundamental research to applied tools for precision oncology.

ANTONIO TOPETE CAMACHOView profile

Researcher

• Nanomedicine
• Biomedical Engineering
• Cancer Therapy
• +5 more

Antonio Topete Camacho is a Ramón y Cajal researcher at the University of Santiago de Compostela, affiliated with the Department of Particle Physics and the Materials Institute (iMATUS). His research focuses on developing nanoplatforms for theranostic applications, including targeted drug delivery systems for cancer treatment, photothermal therapy, and biomedical nanotools. He holds a PhD from the University of Santiago de Compostela (2013), with a thesis on hybrid nanoplatforms for medical applications. Key research areas include: nanoparticle design for cancer therapy, gold nanoshell-based multimodal therapies, and surface functionalization strategies for biomaterials. He also explores genetic risk factors in oncology and translational aspects of precision medicine. His work bridges material science with clinical applications, emphasizing drug delivery mechanisms and biocompatibility studies.

Sebastian BauerView profile

Professor

• Translational Cancer Research
• Soft-Tissue Sarcoma
• Gastrointestinal Stromal Tumor (GIST)
• +7 more

Prof. Dr. Sebastian Bauer is a leading oncologist and academic researcher at the University of Duisburg-Essen, affiliated with the Medical Faculty and the West German Cancer Center (WTZ) at University Hospital Essen. He leads the Translational Sarcoma Research group, focusing on soft-tissue sarcomas, particularly gastrointestinal stromal tumors (GIST). His work integrates molecular oncology, preclinical modeling, and clinical trials to advance targeted therapies. Research Interests: His research spans translational cancer research , oncogenetic signaling pathways , tyrosine kinase inhibitors , preclinical cancer models , and drug development . He investigates mechanisms of resistance in GIST and evaluates novel therapeutic agents in clinical settings. The recent publication trends highlight a strong focus on targeted therapies (e.g., avapritinib, ripretinib), biomarker discovery (ctDNA, neoantigens), and combination therapies in sarcomas. His work frequently appears in high-impact journals such as Nature Communications and Clinical Cancer Research , reflecting significant contributions to clinical oncology and molecular therapeutics. Scientific Awards: No specific awards mentioned in the provided text. Advising and Grants: While specific student names are not listed, Prof. Bauer leads a research group and participates in PhD programs through the ZMB (Center for Molecular Biomedicine), indicating active mentoring. His research is supported by national and international collaborations, including DFG, EU programs, and industry partnerships, particularly in drug licensing and clinical trials. Labs and Teams: He heads the Translational Sarcoma Research group at WTZ Essen, collaborating closely with institutions like TU Dortmund and the Max Planck Institute. His team works on drug discovery, proteogenomics, and clinical trial design, contributing to the development of novel therapies for rare cancers.